# EDGAR Filing Document

**Accession Number:** 0001845459
**File Stem:** 0001213900-26-007794
**Filing Date:** 2026-1
**Character Count:** 21193
**Document Hash:** e5831ed59e653627f20864f1f7d6e439
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-007794.hdr.sgml**: 20260126

**ACCESSION NUMBER**: 0001213900-26-007794

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20260120

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260126

**DATE AS OF CHANGE**: 20260126

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NKGen Biotech, Inc.
- **CENTRAL INDEX KEY:** 0001845459
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40427
- **FILM NUMBER:** 26561442

**BUSINESS ADDRESS:**
- **STREET 1:** 3001 DAIMLER ST,
- **CITY:** SANTA ANA
- **STATE:** CA
- **ZIP:** 92705
- **BUSINESS PHONE:** (949) 396-6830

**MAIL ADDRESS:**
- **STREET 1:** 3001 DAIMLER ST,
- **CITY:** SANTA ANA
- **STATE:** CA
- **ZIP:** 92705

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Graf Acquisition Corp. IV
- **DATE OF NAME CHANGE:** 20210210

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15** **(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 20, 2026**

**NKGen Biotech, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40427** | **86-2191918** |
| **(State or other jurisdiction<br> of incorporation)** | **(Commission File Number)** | **(IRS Employer <br> Identification No.)** |

---

**3001 Daimler Street**

**Santa Ana, CA, 92705**

**(Address of principal executive offices and zip code)**

**Registrant's telephone number, including area code: (949) 396-6830**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Title of each class** | &nbsp;&nbsp;**Trading Symbol(s)** | &nbsp;&nbsp;**Name of each exchange on which registered** |
| &nbsp;&nbsp;**Common Stock, $0.0001 par value per share** | &nbsp;&nbsp;**NKGN** | &nbsp;&nbsp;**OTC Expert Market** |
| &nbsp;&nbsp;**Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share** | &nbsp;&nbsp;**NKGNW** | &nbsp;&nbsp;**OTC Expert Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01. Entry into a Material Definitive Agreement.**

On January 20, 2026, NKGen Biotech, Inc. (the "Company" and formerly known as Graf Acquisition Corp. IV) and Seller (defined below) entered into an eighth amendment (the "FPA Amendment") to the forward purchase agreement, dated as of September 22, 2023 (the "FPA"), initially among the Company, Graf, Meteora Strategic Capital, LLC ("MSC"), Meteora Capital Partners, LP ("MCP") and Meteora Select Trading Opportunities Master, LP ("MSTO" with MSC, MCP, and MSTO collectively, "Seller") for OTC Equity Prepaid Forward Transactions, as amended on December 26, 2023, as further amended on January 2, 2024, January 11, 2024, February 21, 2024, July 12, 2024, September 5, 2024, and December 31, 2024.

Pursuant to the FPA Amendment, the Company and Seller agreed to extend the Valuation Date (as defined in the FPA) to December 31, 2026, or as otherwise described in the FPA Amendment. All other terms and conditions remained unchanged.

On January 23, 2026, the Company and NKGen Operating Biotech, Inc., a Delaware corporation (together with the Company, the "Borrowers"), entered into a second amendment (the "Alpine Second Amendment") to that certain secured promissory note with AlpineBrook Capital GP I Limited, dated January 5, 2026, as amended by that certain amendment to secured promissory note dated January 12, 2026 (the "Note").

The Alpine Second Amendment provides an additional $372,000 of funding to the Borrowers (the "Third Additional New Loan"). As a result, the principal amount of the Note was increased to $26,507,106. The Alpine Second Amendment also clarifies that interest on the Third Additional New Loan accrues from January 23, 2026 (the date on which the Alpine Second Amendment was entered into).

The foregoing description of the FPA Amendment and Alpine Second Amendment do not purport to be complete and are qualified in their entirety by the terms and conditions of the FPA Amendment and Alpine Second Amendment, which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

**Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

The disclosures set forth in Item 1.01 are incorporated by into this Item 2.03 by reference.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Eighth Amendment to Forward Purchase Agreement, dated as of January 20, 2026, among NKGen and Meteora Capital Partners, LP and certain of its affiliates.](ea027345101ex10-1_nkgen.htm) |
| 10.2 | [Amendment No. 2 to Secured Promissory Note issued to the AlpineBrook Capital GP I Limited, dated January 23, 2026.](ea027345101ex10-2_nkgen.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **NKGEN BIOTECH, INC.** | **NKGEN BIOTECH, INC.** |
| Date: January 26, 2026 | /s/ Paul Y. Song | /s/ Paul Y. Song |
|  | Name: | Paul Y. Song |
|  | Title: | Chief Executive Officer |
|  |  | *(Principal Executive Officer)* |

---

## Exhibit 10.1

**Exhibit 10.1**

**FORWARD PURCHASE AGREEMENT CONFIRMATION EIGHTH AMENDMENT**

THIS FORWARD PURCHASE AGREEMENT CONFIRMATION EIGHTH AMENDMENT, dated as of January 20, 2026 (this "Amendment"), is entered into by and among (i) Meteora Capital Partners, LP ("MCP") (ii) Meteora Select Trading Opportunities Master, LP ("MSTO") and (iii) Meteora Strategic Capital, LLC ("MSC") (with MCP, MSTO and MSC collectively as "Seller") and (v) NKGen Biotech, Inc., a Delaware corporation ("NKGN" and formerly known as Graf Acquisition Corp. IV, a Delaware corporation).

Reference is hereby made to the OTC Equity Prepaid Forward Transaction, dated as of September 22, 2023 (the "Confirmation"), the Forward Purchase Agreement Confirmation Amendment, dated as of December 26, 2023, Forward Purchase Agreement Confirmation Second Amendment, dated as of January 2, 2024, and Forward Purchase Agreement Confirmation Third Amendment, dated as of January 11, 2024, Forward Purchase Fourth Amendment, dated as of February 21, 2024, Forward Purchase Agreement Confirmation Fifth Amendment, dated as of July 12, 2024, Forward Purchase Agreement Confirmation Sixth Amendment, dated as of September 5, 2024, and Forward Purchase Agreement Confirmation Seventh Amendment, dated as of December 31, 2024 (as amended from time to time, collectively the "Prior Amendments"), by and among Seller, NKGN and NKGen Operating Biotech, Inc. ("Target" and formerly known as NKGen Biotech, Inc., a Delaware corporation and now a wholly-owned subsidiary of NKGN). Capitalized terms not defined herein shall have the meanings assigned to such terms in the Confirmation.

On September 29, 2023, NKGN and Target completed the Business Combination, and accordingly, the Seller delivered a Pricing Date Notice to commence the Transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Amendment</u>: The parties hereto agree to amend the Confirmation as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. The Section titled "Valuation Date" shall be deleted in its entirety and replaced with the
following:

---

| | |
|:---|:---|
| Valuation Date: | The earlier to occur of (a) December 31, 2026 and (b) the date specified by Seller in a written notice to be delivered to Counterparty at Seller's discretion (which Valuation Date shall not be earlier than the day such notice is effective) after the occurrence of any of (w) a VWAP Trigger Event, (x) a Delisting Event, (y) a Registration Failure or (z) unless otherwise specified therein, upon any Additional Termination Event. |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Non-Reliance</u>. Seller acknowledges and agrees that NKGN is in possession of non-public information about NKGN and its securities that has not been provided to Seller and that may or may not be material or superior to information available to Seller, and that Seller, in entering into this Amendment, has not relied and is not relying on any representations, warranties or other statements whatsoever, whether written or oral (from or by NKGN or any Person acting on their behalf) other than those expressly set out in this Amendment (or other related documents referred to herein) and that it will not have any right or remedy rising out of any representation, warranty or other statement not expressly set out in this Amendment or the Confirmation. Seller hereby waives any claim, or potential claim, it has or may have against NKGN and its officers and directors relating to NKGN's possession of material non-public information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>No Other Amendments</u>. All other terms and conditions of the Confirmation and Prior Amendments shall remain in full force and effect and the Confirmation shall be read and construed as if the terms of this Amendment were included therein by way of addition or substitution, as the case may be.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Execution in Counterparts</u>. This Amendment may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall constitute one and the same agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Ratification</u>. The terms and provisions set forth in this Amendment modify and supersede all inconsistent terms and provisions set forth in the Confirmation and, except as expressly modified and superseded by this Amendment, the terms and provisions of the Confirmation are ratified and confirmed and continue in full force and effect. All parties hereby agree that the Confirmation and Prior Amendments, as amended by this Amendment, shall continue to be legal, valid, binding and enforceable in accordance with their terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK (WITHOUT GIVING EFFECT TO THE CONFLICT OF LAWS PROVISIONS THEREOF).

[signatures page follows]

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed and delivered by their duly authorized officers as of the date first above written.

---

| | |
|:---|:---|
| **METEORA STRATEGIC CAPITAL, LLC** | **METEORA STRATEGIC CAPITAL, LLC** |
| **METEORA SELECT TRADING** | **METEORA SELECT TRADING** |
| **OPPORTUNITIES MASTER, LP; AND** | **OPPORTUNITIES MASTER, LP; AND** |
| **METEORA CAPITAL PARTNERS, LP** | **METEORA CAPITAL PARTNERS, LP** |
| By: | /s/ Vikas Mittal |
| Name: | Vikas Mittal |
| Title: |  |
| **NKGEN BIOTECH, INC.** | **NKGEN BIOTECH, INC.** |
| By: | /s/ Paul Song |
| Name: | Paul Song |
| Title: | Chief Executive Officer |

---

## Exhibit 10.2

**Exhibit 10.2**

**AMENDMENT NO. 2 TO SECURED PROMISSORY NOTE**

This **Amendment No. 2 to Secured Promissory Note**, dated January 23, 2026 (the "***Amendment***") is entered into by and among **NKGen Biotech, Inc.**, a Delaware corporation (the "***Company***"), **NKGen Operating Biotech, Inc.**, a Delaware corporation (the "***Company Sub***," together with the Company, the "***Borrowers***," and each, a "***Borrower***") and AlpineBrook Capital GP I Limited ("***Lender***"). Capitalized terms used in this Amendment and not otherwise defined in this Amendment have the respective meanings ascribed to them in the Note (as defined below).

**Recitals**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A.** Borrowers issued that certain secured promissory note (the "***Original Note***") on January 5, 2026 to Lender in the principal amount of US$25,840,106, and the parties entered into an amendment to secured promissory note on January 12, 2026 (the "***Amendment No. 1***," together with the Original Note, the "***Note***") to increase the principal amount of the Original Note to US$26,135,106.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B.** Borrowers have requested Lender to extend an additional US$372,000 new loan (the "***Third Additional New Loan***") to Borrowers and the parties desire to amend the Note as set forth in this Amendment.

**Agreement**

In consideration of the mutual covenants and agreements set forth herein and for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1. Principal Amount**. The amount corresponding to "Principal Amount of Note" at the beginning of the Note is hereby amended and restated to be "US$26,507,106."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2. Obligations**. For all purposes under the Note, the term "***Obligations***" shall mean all present and future obligations and liabilities (whether actual or contingent and whether owed jointly or severally or in any other capacity whatsoever) of Borrowers to Lender, under or pursuant to the Note, as amended by this Amendment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3. Additional New Loan**. For all purposes under the Note, the term "***Additional New Loan***" shall mean the US$300,000 extended by Lender to Borrowers on January 5, 2026, the US$295,000 extended by Lender to Borrowers in connection with Amendment No. 1 (the "***Second Additional New Loan***"), and the Third Additional New Loan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4. Interest**. Section 1(c) of the Note is hereby amended by deleting the new sentence inserted under Section 4 of the Amendment No. 1 in its entirety and replacing with the bellow:

"Interest on US$25,840,106 of the Principal Amount shall start to accrue on January 5, 2026, interest on the Second Additional New Loan shall start to accrue on January 12, 2026, and interest on the Third Additional New Loan shall start to accrue on January 23, 2026."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5. U.S. Personal Property**. Section 1(f)(i)(ii) of the Note is hereby deleted in its entirety and replaced by the below:

"(ii) conditioned on obtaining any required third-party consents, approvals or intercreditor arrangements from East West Bank and BDW Investments LLC,"

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6. Convertible Loans**. Section 1 of the Note is hereby amended by inserting the following as the new sub-section (g):

"(g) Borrowers shall use best efforts to engage in good faith negotiations with Lender regarding potential amendments to the Note, or any related agreements between Borrowers and Lender, with a view toward consolidating such documents into one or more convertible loan arrangements on terms and conditions mutually satisfactory to the Borrowers and the Lender."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7. Public Disclosure**. Section 1 of the Note is hereby amended by inserting the following as the new sub-section (h):

"(h) Borrowers shall not, and shall procure that all Group Companies shall not, make any securities filing, issue any press release, or otherwise make any public disclosure regarding or involving Lender or any transaction with Lender without first providing the proposed disclosure to Lender for review. Lender shall have twenty-four (24) hours from delivery of such proposed disclosure to notify Borrowers in writing of any objections or required changes, which consent shall not be unreasonably withheld, conditioned, or delayed. If Lender does not provide written notice of objection within such twenty-four (24) hour period, Lender shall be deemed to have approved the proposed disclosure. Nothing herein shall restrict Borrowers from making any disclosure required by law, provided that Borrowers shall, to the extent reasonably practicable, give Lender prior notice and a reasonable opportunity to comment.."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8. Representations and Warranties**. Each Borrower hereby jointly and severally represents and warrants to Lender that the representations and warranties set forth under Section 5 of the Note are true and correct in all respects as of the date hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9. Effect of Amendment**. Upon the effectiveness of this Amendment, each reference in the Note to "this Note," "hereunder," "hereof," "herein," or words of like import shall mean and be a reference to the Note, as amended by this Amendment, and each reference to the Note in any other document, instrument or agreement executed or delivered in connection with the Note shall mean and be a reference to the Note, as amended by this Amendment. All other terms and conditions of the Note not specifically amended by this Amendment will be unaffected hereby and remain in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10. Miscellaneous**. Section 7 (Miscellaneous Provisions) of the Note is hereby incorporated by reference and shall apply to this Amendment, *mutatis mutandis*.

[Signature Page Follows]

**In Witness Whereof**, the undersigned have caused this Amendment No. 2 to Secured Promissory Note to be executed and delivered on the date first above written.

---

| | | |
|:---|:---|:---|
| **Borrowers:** | **Borrowers:** | **Borrowers:** |
| **NKGEN BIOTECH, INC.** | **NKGEN BIOTECH, INC.** | **NKGEN BIOTECH, INC.** |
| By: | <u>/s/ Paul Song</u> | <u>/s/ Paul Song</u> |
|  | Name: | Paul Y. Song |
|  | Title: | Chief Executive Officer |
| Address: | Address: |  |
| Email: | Email: |  |
| **NKGEN OPERATING BIOTECH, INC.** | **NKGEN OPERATING BIOTECH, INC.** | **NKGEN OPERATING BIOTECH, INC.** |
| By: | <u>/s/ Paul Song</u> | <u>/s/ Paul Song</u> |
|  | Name: | Paul Y. Song |
|  | Title: | Chief Executive Officer |
| Address: | Address: |  |
| Email: | Email: |  |

---

[SIGNATURE PAGE TO AMENDMENT NO. 2 TO SECURED PROMISSORY NOTE]

**In Witness Whereof**, the undersigned have caused this Amendment No. 2 to Secured Promissory Note to be executed and delivered on the date first above written.

---

| | | |
|:---|:---|:---|
| **Lender:** | **Lender:** | **Lender:** |
| **ALPINEBROOK CAPITAL GP I LIMITED** | **ALPINEBROOK CAPITAL GP I LIMITED** | **ALPINEBROOK CAPITAL GP I LIMITED** |
| By: | /s/ Hanhan Xu | /s/ Hanhan Xu |
|  | Name: | Hanhan Xu |
|  | Title: | Managing Director |
| Address: | Address: |  |
| Email: | Email: |  |

---

[SIGNATURE PAGE TO AMENDMENT NO. 2 TO SECURED PROMISSORY NOTE]